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Antiviral Function of APOBEC3G Can Be
Dissociated from Cytidine Deaminase Activity
in rpoB can be evaluated by screening for the frequency
of acquired rifampicin resistance (rifR) relative to cell
viability.Whereasmutationsmade in theN-terminal resi-
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and Ann M. Sheehy1,* dues had very little effect on acquired rifampicin resis-
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Guy’s, King’s, and St. Thomas’ School of Medicine cally decreased the frequency of rifR bacterial colonies
(e.g., the H257R mutant-induced rifampicin resistanceKing’s College London
London SE1 9RT is decreased17-fold relative towild-type APOBEC3G).
Not unexpectedly, the mutational activity of the double-United Kingdom
2Department of Pathobiology point mutants was also significantly suppressed. These
results implicate the C-terminal active site as necessaryUniversity of Washington
Seattle, Washington 98195 for the DNA-mutating function of APOBEC3G and seem
to suggest that the N-terminal active site is dispensable
for this activity. It is also worth noting that the N-terminal
active site contains a proline at position 2 rather than
the expected alanine or valine. It is possible that theSummary
positioning of this proline distorts the local structure of
the active site, perturbing the Zn2 coordination. OurThe antiretroviral activity of the cellular enzyme APO-
results support the inference that the C-terminal regionBEC3G [1] has been attributed to the excessive deami-
is primarily responsible for the DNA-mutating functionnation of cytidine (C) to uridine (U) in minus strand
of APOBEC3G.reverse transcripts, a process resulting in guanosine
These mutant proteins were next tested in a single-(G) to adenosine (A) hypermutation of plus strand
round virus infection assay for their ability to regulate vif-DNAs [2–5]. The HIV-1 Vif protein counteracts APO-
deficient (vif) HIV-1 infection (Figure 1B). Surprisingly,BEC3G by inducing proteasomal degradation and ex-
relative to the wild-type APOBEC3G, none of the single-clusion from virions through recruitment of a cullin5
point mutant proteins were significantly affected in theirECS E3 ubiquitin ligase complex [6–13]. APOBEC3G
ability to function as antiviral factors. Although titratingbelongs to the APOBEC protein family, members of
down the expression of the mutant proteins amelioratedwhich possess consensus (H/C)-(A/V)-E-(X)24-30-P-
their antiviral activity (data not shown), all of themutantsC-(X)2-C cytidine deaminasemotifs [14]. Earlier analy-
retained more than 60% of the antiviral activity of theses of APOBEC-1 have defined specific residues that
wild-type protein under the experimental conditionsare important for zinc coordination, proton transfer,
used here. Additionally, each mutant was examined forand, therefore, catalysiswithin thismotif [15]. Because
activity against wild-type HIV-1; all exhibited Vif-sensi-APOBEC3G contains two such motifs, we used site-
tivity and were therefore unable to suppress wild-typedirectedmutagenesis of conserved residues to assess
virion infectivity significantly. Analyzed together with theeach region’s contribution to anti-HIV-1 activity. Sur-
bacterial editing assay, this rather unexpected resultprisingly, whereas either the N- or C-terminal domain
suggests that impairment of the editing function of APO-could confer antiviral function in tissue culture-based
BEC3G does not necessarily inhibit APOBEC3G’s abilityinfectivity assays, only an intact C-terminal motif was
to suppress HIV-1 infection in this context.essential for DNA mutator activity. These findings re-
When the double point mutant proteins were exam-veal the nonequivalency of APOBEC3G’s N- and
ined for their effects on infectivity, the loss of APO-C-terminal domains and imply that APOBEC3G-medi-
BEC3G function was far more dramatic. In fact, the ob-ated DNA editing may not always be necessary for
served loss of activity for each double mutant exceededantiviral activity. Accordingly, we propose that APO-
what might be expected from the corresponding singleBEC3G can achieve an anti-HIV-1 effect through an
point mutant data. For example, whereas E67Q andundescribed mechanism that is distinct from cytidine
E259Q each retain 80%–90%antiviral activity, the corre-deamination.
sponding double mutant was inactive. These results
support the idea that while the highly conserved resi-
Results and Discussion dues of one “deaminase domain” may be dispensable,
the matching residues in the other are then essential.
Initially, wild-type and mutant APOBEC3G (apolipopro- Thus, antiviral activity appears to be dependent on one
tein B mRNA-editing enzyme-catalytic polypeptide-like of the domains being intact, but with little discrimination
3G) proteins (Table 1) were assayed for their ability to as to which one.
function as DNA mutators in an E. coli-based assay In light of the suggestion that the antiviral activity of
(Figure 1A). This assay is a readout of the ability of a APOBEC3G can bemediated through amechanism that
transduced gene to mutate the RNA polymerase B gene is independent of its cytidine deaminase function, we
(rpoB) in the KL-16 strain of bacteria [16, 17]. Mutations next sequenced viral cDNAs recovered from cells chal-
lenged with vif virions produced in the presence of
wild-type ormutant APOBEC3Gproteins [18]. Themuta-*Correspondence: ann.sheehy@kcl.ac.uk
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Table 1. Summary of APOBEC3G Mutations
Consensus: H-(A/V)-E-(X)24–30-P-C-(X)2-C
N-Terminal Active Site C-Terminal Active Site aa Change
H-P-E-(X)24–30-P-C-(X)2-C H-A-E-(X)24–30-P-C-(X)2-C Wild-type
R-P-E-(X)24–30-P-C-(X)2-C H-A-E-(X)24–30-P-C-(X)2-C H65R
H-P-E-(X)24–30-P-C-(X)2-C R-A-E-(X)24–30-P-C-(X)2-C H257R
R-P-E-(X)24–30-P-C-(X)2-C R-A-E-(X)24–30-P-C-(X)2-C H65R and H257R
H-P-Q-(X)24–30-P-C-(X)2-C H-A-E-(X)24–30-P-C-(X)2-C E67Q
H-P-E-(X)24–30-P-C-(X)2-C H-A-Q-(X)24–30-P-C-(X)2-C E259Q
H-P-Q-(X)24–30-P-C-(X)2-C H-A-Q-(X)24–30-P-C-(X)2-C E67Q and E259Q
H-P-E-(X)24–30-P-S-(X)2-C H-A-E-(X)24–30-P-C-(X)2-C C97S
H-P-E-(X)24–30-P-C-(X)2-C H-A-E-(X)24–30-P-S-(X)2-C C288S
H-P-E-(X)24–30-P-S-(X)2-C H-A-E-(X)24–30-P-S-(X)2-C C97S and C288S
H-P-E-(X)24–30-P-C-(X)2-S H-A-E-(X)24–30-P-C-(X)2-C C100S
H-P-E-(X)24–30-P-C-(X)2-C H-A-E-(X)24–30-P-C-(X)2-S C291S
H-P-E-(X)24–30-P-C-(X)2-S H-A-E-(X)24–30-P-C-(X)2-S C100S and C291S
The consensus sequence of the active site for cytidine deaminases is shown at the top. Mutations were made with oligonucleotide site-
directed mutagenesis (Invitrogen). The underlined letters indicate the change in amino acid for the corresponding mutant.
tions identified in cloned cDNAs are catalogued in Table cently implicated as being important for the packaging
of APOBEC3G into virions [22–25]. We used continuous2. As shown previously, analysis of the mutational spec-
tra confirms that wild-type APOBEC3G induces high sucrose gradients to isolate virions made in the pres-
ence of either wild-type or mutant APOBEC3G proteins,levels of G to A hypermutation (13% of all G residues
mutated). The rates of mutation induced by the N-ter- and then we examined their contents by immunoblot
[1]. As seen in Figures 2A and 2B, the mutant proteinsminal mutants (H65R and C97S) also correlated with the
antiviral activity, although the actual rates were some- were readily detectable in purified virions (upper panels)
and were present at approximately similar levels. There-what lower. To our surprise, and in good agreement with
the results of the E. coli mutator assays (Figure 1A), we fore, although the cytidine deaminase activity of the
C-terminal mutants is not required for their ability towere unable to detect any significant mutational activity
in any of the infections carried out in the presence of suppress virion infectivity, we were unable to dissociate
the ability of these proteins to be packaged into assem-the C-terminal mutants (Table 2), despite the fact that
these proteins displayed strong antiviral effects, ranging bling virions from their antiviral function. Finally, it could
be argued that editing-deficient APOBEC3G mutantsfrom 53%–97% (Figure 1B; Table 2). These data suggest
that an antiviral function of APOBEC3G can be exerted interfere with infection in a more fundamental manner
than the wild-type protein (for instance, by severely di-independently of its DNA deaminase activity.
We considered the possibility that disruption of the minishing reverse transcription).We consider this expla-
nation to be unlikely: First, extensively edited reverseC-terminal active site created mutant proteins in which
this domain acquired a dominant-interfering phenotype transcripts were still readily recovered in the mixing ex-
periment discussed earlier (Table S1), and second, pre-over the N-terminal site, such that the assumed lack of
enzymatic activity of the N-terminal site was, instead, liminarymeasurements of viral cDNA levels indicate that
the early phases of reverse transcription are as efficientdue to suppression. Recently, a number of groups have
experimentally shown the dimerization capabilities of in the presence of these C-terminal mutants as they are
with wild-type APOBEC3G (data not shown).several APOBEC family members [19–21]. We exploited
these observations to ask whether mutant carboxy-ter- Previous reports of APOBEC3G-induced hypermuta-
tion have correlated cytidine deaminase activity withminal domains can influence the activity of editing-
active domains that may be in close spatial proximity. antiviral function [3, 5, 26]. Our results with cultured cell
systems and a panel of mutant APOBEC3G proteinsExpression constructs for wild-type APOBEC3G and the
E259Q mutant were cotransfected (at a 1:6 ratio) into indicate that this is not always the case. In particular,
we demonstrate that, under the described experimental293T cells, and both virion infectivity and cDNA editing
capacity were examined (see Table S1 in the Supple- conditions, the cytidine deamination function of APO-
BEC3G can be separated from antiviral activity. We notemental Data available with this article online). The pres-
ence of the E259Q protein had no effect on the extent of that our study differs from these earlier reportings in
that we employed proteins that had not been epitopeediting mediated by the wild-type APOBEC3G protein,
arguing against the idea of a dominant-negative effect. tagged. In our experience, we have observed that a
terminal tag can not only interfere with mutant proteinBecause the C-terminal mutants fail to edit viral cDNA
in target cells, we questioned whether this protein was expression but can impair function in the E. coli-based
assay and during virus infection (unpublished data). Ourstill packaged into HIV-1 virions. In APOBEC-1, several
residues within the active site have been shown to also data raise the possibility that the APOBEC3G-induced
viral-cDNA hypermutation that has been observed bybe critical for RNA binding [15]. If these conserved resi-
dues within the C-terminal active site of APOBEC3G many groups may be an observable side effect and
may not always be central to the antiviral function ofplay a similar role, then their replacement could also
influence RNA binding, an attribute that has been re- APOBEC3G. In other words, the finding that APOBEC3G
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Figure 1. The Cytidine Deaminase Activity of
APOBEC3G Is Not Required for an Antiviral
Effect
(A) The ability of wild-type or mutated APO-
BEC3G proteins to mutate E. coli DNA. APO-
BEC3G-expressing vectors were transformed
into bacteria, and the resulting induction of rif-
ampicin resistancewasquantitated by count-
ing rifR colonies (relative to viable cell counts).
Wild-type APOBEC3G typically induced rif-
ampicin resistance by30-fold relative to the
vector control. The mutation rates for the mu-
tant APOBEC3Gproteins are plotted as aper-
centage of that seen with wild-type protein
(set at 100%). Error bars represent the stan-
dard deviation.
The lower panel shows immunoblots confirm-
ing comparable expression of the mutant
APOBEC3G proteins in bacteria.
(B) Antiviral function of APOBEC3G mutant
proteins. vif-deficient (vif) HIV-1 was pro-
duced in 293T cells transiently transfected
with APOBEC3G expression vectors (1:1
plasmid ratio of proviral and APOBEC3G ex-
pression plasmid). Virus-containing superna-
tants were harvested at 24 hr and quantitated
with a p24Gag ELISA (enzyme-linked immuno-
sorbent assay). Normalized inocula were
used to infect the C8166-CCR5/HIV-LTR CAT
indicator cell line, in which infectivity is corre-
lated with the induction of CAT activity [30],
and the antiviral activity of each mutant pro-
tein is presented as a percentage of that seen
for wild-type APOBEC3G. Here, the wild-type
APOBEC3Gwas HA-tagged at its C terminus:
This modification does not interfere with the
assayable antiviral function of this protein.
Error bars represent the standard deviation.
The lower panel is an immunoblot confirming
expression of the mutant APOBEC3G pro-
teins in producer cell lysates.
variants that lack cytidine deaminase function can still antiviral effects. For instance, different domains of APO-
BEC3G may function independently in its role as animpose a significant antiviral effect indicates the exis-
tence of an additional cellular pathway (or mechanism) antiviral factor. Structure-function analyses of AID (acti-
vation-induced cytidine deaminase), another member offor resisting HIV-1 infection.
Recent studies examining the impact of APOBEC3G the APOBEC family, have led to the identification of two
separable domains independently responsible for theon hepatitis B viral (HBV) infection also suggest that
APOBEC3Gmay exert its antiviral effect inmultiple ways primary functions of this protein, class-switch recombi-
nation and somatic hypermutation, both of which are[27, 28]. Specifically, these investigations showed that
although APOBEC3G exhibited a strong suppressive ef- key processes in antibody diversification [29]. Although
the mutations that illustrate this dissociation are notfect againstHBV, the small amount of DNA found associ-
ated with viral cores lacked G to A mutations (at least within the core cytidine deamination domain of AID, the
results support the premise that different domainswithinin the Huh7 hepatoma cell line). These and our results
underscore the need for continuing reevaluation of the AID may function independently.
With respect to APOBEC3G, it would be interestingpossible mechanisms involved in APOBEC3G-mediated
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Table 2. The Loss of Detectable Hypermutation Does Not Block APOBEC3G Antiviral Activity
Average Average
Antiviral Total G to A G to A
Activity Clones Total Bases Total G to A Other Mutations Mutations
APOBEC3G (%) Sequenced Sequenced Mutations Mutations Mutations per Sequence per 100 bp
None 0 10 6,500 3 1 2 0.1 0.02
Wild-type 100 8 5,200 163 155 8 19 2.98
H257R 54 10 6,500 3 0 3 0.0 0.00
E259Q 97 10 6,500 1 1 0 0.1 0.02
C288S 77 10 6,500 8 8 0 0.8 0.12
C291S 53 9 5,850 6 1 5 0.1 0.02
H65R 87 16 10,400 149 136 13 9 1.31
C97S 84 10 6,500 119 112 7 11 1.72
vif-deficient (vif) HIV-1 virions were produced in 293T cells transiently transfected with the APOBEC3G expression constructs and were then
used to infect the C8166-CCR5/HIV-1 LTR CAT indicator cells. At 24 hr, infectivity was measured as an induction of CAT activity, and
total DNA was isolated from the infected cells and subjected to high-fidelity PCR (Advantage HF-2 PCR kit, Clontech) with HIV-1-specific
oligonucleotides. The PCR product was cloned into pBluescript and sequenced. The number of bases sequenced is indicated. It should be
noted that the reported antiviral activity was from this single experiment, but the activities all fall within the average antiviral activities reported
in Figure 1B.
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Figure 2. Incorporation of Mutant APOBEC3G Protein into Virions
(A and B) Both wild-type and mutant APOBEC3G proteins are efficiently packaged into virions. The purified virions analyzed in (A) and (B)
are from independent experiments, and wild-type APOBEC3G packaging was examined within each experiment.
The upper panels are immunoblots verifying the presence of APOBEC3G proteins within virions produced from transfected 293T cells (as for
Figure 1B). Viral supernatants were harvested at 24 hr after transfection, and virions were isolated by continuous sucrose gradient purification
[1]. E67Q and E259Q were also packaged to similar levels (data not shown).
The lower panels are immunoblots probed with an antibody specific for p24Gag (loading control).
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